zebraMD

zebraMD: an AI powered, EMR integrated and solo-standing clinical decision making tool for genomic precision medicine. Rare disease is not that rare: Your chances of getting any one of them is 1/10, the same risk as getting Diabetes. Over 500 Million people are affected by a rare or genetic disease worldwide, half of them are children, and 30% of them will die within the first 5 years of their life due to their disease. On average, it takes 12-15 years from onset of symptoms to be diagnosed with one of the >10,000 currently known rare and genetic diseases, much longer for patients who reside in rural and underserved communities. Inability to access specialty care leads to a diagnostic and therapeutic delay, causing preventable secondary comorbidities and earlier, much higher mortality rates. Lack of early recognition, intervention and appropriate long term management places a significant burden on the healthcare system; Over half the direct medical cost in the US is generated by patients with a rare or genetic disease, even though they only represent a fraction of the total patient population; it costs ~$27-29k more to treat a patient with a rare/genetic disease per year than comparable chronic disease patients primarily due to inability to access specialist treatment leading to preventable hospitalizations. Not placing a patient on appropriate therapeutics if one is even available, causes an additional 21% higher cost of annual medical management, despite the 5x higher cost of orphan drugs. Project zebraMD aims to provide evidence based specialty care anywhere, right at the point of care, no matter the patient's zip code, while utilizing longitudinal clinical data models to help find new therapies for rare and genetic disease. Genomics underlie every disease process; our tool can be used in any specialty for any patient to deliver precision medicine on a population level scale, reducing healthcare burden while improving patient outcomes. info@zebraMD.org